Karuna Therapeutics Inc. (KRTX) Misses Q2 EPS by 11c

Karuna Therapeutics Inc. (NASDAQ: KRTX) reported Q2 EPS of ($2.17), $0.11 worse than the analyst estimate of ($2.06). Revenue for the quarter came in at $5.28 million.

For earnings history and earnings-related data on Karuna Therapeutics Inc. (KRTX) click here.

You May Also Be Interested In

• Karyopharm Therapeutics (KPTI) Misses Q2 EPS by $1.01, Beats on Revenue; Offers FY26 Revenue Guidance
• Ascendis Pharma (ASND) Tops Q2 EPS by 132c
• Beyond Air, Inc. (XAIR) Tops Q1 reported Q1 Revenue ; Offers Guidance